

ACCELOVANCE, INC.



OVERVIEW

Accelovance is an award winning, full service clinical Contract Research Organization (CRO) focused on vaccine, oncology, and general medicine Phase I-IV programs. Accelovance provides global CRO services to pharmaceutical companies, biotech, CROs, and academic institutions.


OPTIMAL RESEARCH, LLC



OVERVIEW

Optimal Research is a Site Management Organization (SMO) providing clinical site solutions to pharmaceutical and biotech companies, medical device companies, and CROs. The company is focused on men and women's health, geriatrics, vaccine, oncology, and pediatric heart conditions.

A MULTI-TRANSACTIONAL PARTNERSHIP RESULTING IN VALUE-ADD FOR ALL PARTIES



KNOWLEDGE + EXPERIENCE

STRATEGY + AGILITY

INSIGHT + ACTION

Bourne Partners provides strategic and financial advisory services to clients throughout the business evolution cycle. We play an active role in helping businesses grow and maximize outcomes by creating long-term, profitable relationships that extend beyond single transactions.

It is our focus on relationships that has yielded us a track record of client satisfaction.

BOURNE PARTNERS ADVISES ACCELOVANCE ON SALE OF CLINICAL CRO AND SITE NETWORK, OPTIMAL RESEARCH

ROCKVILLE, MD - In January 2017, Accelovance, Inc. ("Accelovance"), a global contract research organization (CRO) focused on oncology, vaccines and general medicine, engaged Bourne Partners ("Bourne") to find an appropriate buyer for the company. Fifteen months later all company assets were sold through two successful transactions.

Upon initial review, Bourne Partners sought to run a typical CRO sell-side process and began the general course of action. After investigating the increased M&A activity around Site Management Organizations (SMOs), Bourne Partners and Accelovance changed the approach and chose to run a highly targeted process focusing solely on a handful of the largest CRO's, all known by Bourne to be actively seeking SMO acquisition opportunities. It was clear that Accelovance would maximize its value by carving out its SMO, Optimal Research. Optimal Research was sold to Synexus, part of PPD's Accelerated Enrollment Solutions business unit, for an undisclosed amount in Q4 2017.

In keeping with Accelovance's planned timeline, the Bourne team sought an acquirer for the remaining Clinical CRO division. After running a second sell-side process, Bourne found success in the sale of all remaining assets to Linical Co., a leading, Asia-based CRO providing services in the areas of oncology and central nervous system to pharmaceutical companies worldwide.

Stephen Trevisan, President and Chief Executive Officer of Accelovance, stated, "Bourne Partners' experienced execution team, deep domain knowledge and extensive strategic and PE relationships were critical in maximizing the value of the sale of Accelovance and Optimal Research. I highly recommend them as a sell-side advisor in the Clinical CRO and Sites Network space."

Banks Bourne, Chief Executive Officer of Bourne Partners, said, "We are pleased to play a part in the sale of Optimal Research, as well as the transpacific connection of Accelovance and Linical. These transactions serve as a testament to the strong company Steve Trevisan and team have built over the past 13 years."

About Accelovance, Inc.

Accelovance is an award winning, clinical development CRO focused on oncology, vaccine, dermatology, pain, nutrition and women's health (Phase I-IV programs). Providing global full CRO services to pharmaceutical companies, biotechs, CROs, and academic institutions, Accelovance supports client needs by leveraging operational knowledge and patient recruitment strategies that result in successful clinical trials. Established in 2005 with a corporate mission to improve the quality and predictability in clinical research, Accelovance has made significant strides in the industry by combining strong business and operational perspective with clinical and medical expertise. For more information, visit www.accelovance.com.

About Optimal Research

Optimal Research provides clinical site solutions to pharmaceutical and biotech companies, medical device companies, and contract research organizations (CROs) seeking research sites to conduct clinical research studies in a high quality manner. In addition to the six core sites that it owns, Optimal utilizes its oncology and pediatric site network to provide integrated site solutions that meet our client's needs. Optimal is the intersection where pharmaceutical/biotech companies and patients find excellence in clinical research. Specifically, Optimal provides clinical site infrastructure and staffing to meet the requirements of the clinical trial protocols for men's and women's health, geriatrics, vaccine, oncology, and pediatric health conditions. For more information, visit www.optimalsites.net.

About Bourne Partners

Bourne Partners is a financial services firm specializing in the pharma, pharma services and consumer health sectors. Located in Charlotte, N.C., the company offers investment banking and advisory services, as well as direct investment opportunities. As owners and operators with over 15 years of experience, Bourne Partners strives to enrich the lives and improve the health and well-being of their partners and patients across the globe by facilitating the efficient movement of capital through the global healthcare sector. For more information, visit www.bourne-partners.com.